Fundraising Fox

Myrtelle

New York, US · Founded 2021 · Delaware corporation

Myrtelle develops gene therapies for neurological diseases, particularly white matter disorders of the central nervous system. The company is conducting clinical trials for Canavan disease using novel AAV vector technology to target oligodendrocytes.

AI & Machine LearningBiotechDeep TechHealthtech

Founders & leadership

AS
Adrian StecykinChief Executive Officer & Co-founder
MP
Mark PykettinExecutive

Board

CB
Chrystyna BedrijBoard director
MM
Michael MuhonenBoard director
FX
Fay XingBoard director
TB
Thomas BartonBoard director
LP
Laurie PlatekBoard director
DY
Debra YuBoard director

Reported raises · per SEC filings

Form D private placements

$89.9M disclosed across 6 rounds · 2021–2026

▶$16.7MraisedJul 2026 · 3 investors · Biotechnology
Rule 506(b)
Myrtelle has filed a notice of an exempt offering of securities to raise $30 Million in New Funding. - intelligence360intelligence360.news · Jul 2026Healthcare Private Placement and M&A Transactions Reviewjhodsonwalker.substack.com · Jul 2026
Officers, directors & promoters on the filing
  • Adrian StecykExecutive Officer, Director
  • Chrystyna BedrijDirector
  • Laurie PlatekDirector
  • Debra YuDirector
  • Michael MuhonenDirector
  • Thomas BartonDirector
Offering amount
$30M
Amount sold
$16.7M
Minimum investment
$25K
First sale
Jun 2026
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$30.5MraisedDec 2025 · 21 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas BartonDirector
  • Adrian StecykExecutive Officer, Director
  • Laurie PlatekDirector
  • Debra YuDirector
  • Michael MuhonenDirector
  • Chrystyna BedrijDirector
Offering amount
$55.2M
Amount sold
$30.5M
Minimum investment
$25K
First sale
Dec 2025
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7.5MraisedMar 2025 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Michael MuhonenDirector
  • Chrystyna BedrijDirector
  • Fay XingDirector
  • Thomas BartonDirector
  • Adrian StecykExecutive Officer, Director
  • Laurie PlatekDirector
Offering amount
$15M
Amount sold
$7.5M
Minimum investment
$50K
First sale
Mar 2025
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6MraisedJun 2024 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Adrian StecykExecutive Officer, Director
  • Laurie PlatekDirector
  • Thomas BartonDirector
  • Michael MuhonenDirector
  • Fay XingDirector
  • Chrystyna BedrijDirector
Offering amount
$10M
Amount sold
$6M
Minimum investment
$10K
First sale
May 2024
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15.7MraisedOct 2022 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Laurie PlatekDirector
  • Chrystyna BedrijDirector
  • James HuangDirector
  • Mark PykettExecutive Officer, Director
Offering amount
$30M
Amount sold
$15.7M
Minimum investment
$10K
Sales commissions
$941K
Placement agents
Raymond James & Associates, Inc.
First sale
Oct 2022
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$13.5MraisedJul 2021 · 27 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark PykettExecutive Officer
  • Chrystyna BedrijExecutive Officer
  • Laurie PlatekExecutive Officer
Offering amount
$20.5M
Amount sold
$13.5M
Minimum investment
$10K
Finders' fees
$400K
Placement agents
Raymond James & Associates, Inc.
First sale
Apr 2021
Incorporated
Limited Liability Company, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Myrtelle has filed a notice of an exempt offering of securities to raise $30 Million in New Funding. - intelligence360intelligence360.news · Jul 2026Healthcare Private Placement and M&A Transactions Reviewjhodsonwalker.substack.com · Jul 2026

Frequently asked questions

What does Myrtelle do?
Myrtelle develops gene therapies for neurological diseases, particularly white matter disorders of the central nervous system. The company is conducting clinical trials for Canavan disease using novel AAV vector technology to target oligodendrocytes.
How much funding has Myrtelle raised?
Myrtelle has disclosed $89.9M raised across 6 rounds.
Where is Myrtelle headquartered?
Myrtelle is headquartered in New York, US.
Myrtelle — Investors & Founders | Fundraising Fox